Radia M. Johnson

Radia M. Johnson

Auto-generated profile, based on publicly available information

Radia M. Johnson

Department of Discovery Oncology, Genentech, South San Francisco, California

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZZZi-Ming Zhao
Zi-Ming Zhao
SYSusan E Yost
Susan E Yost
KHKatherine E. Hutchinson
Katherine E. Hutchinson
SLSierra Min Li
Sierra Min Li
YYYate-Ching Yuan
Yate-Ching Yuan
YYYuan Yuan
Yuan Yuan
Triple negative breast cancer (TNBC) is aggressive with limited treatment options upon recurrence. Molecular discordance between primary and metastatic TNBC has been observed, but the degree of biological heterogeneity has not been fully explored. Furthermore, genomic evolution through treatment is poorly understood. In this study, we aim to characterize the genomic changes between paired primary and metastatic TNBCs through transcriptomic and genomic profiling, and to identify genomic alterations which may contribute to chemotherapy resistance. Genomic alterations and mRNA expression of 10 paired primary and metastatic TNBCs were determined through targeted sequencing, microarray analysis, and RNA sequencing. Commonly mutated genes, as well as differentially expressed and co-expressed genes were identified. We further explored the clinical relevance of differentially expressed genes between primary and metastatic tumors to patient survival using large public datasets. Through gene expression profiling, we observed a shift in TNBC subtype classifications between primary and metastatic TNBCs. A panel of eight cancer driver genes (CCNE1, TPX2, ELF3, FANCL, JAK2, GSK3B, CEP76, and SYK) were differentially expressed in recurrent TNBCs, and were also overexpressed in TCGA and METABRIC. CCNE1 and TPX2 were co-overexpressed in TNBCs. DNA mutation profiling showed that multiple mutations occurred in genes comprising a number of potentially targetable pathways including PI3K/AKT/mTOR, RAS/MAPK, cell cycle, and growth factor receptor signaling, reaffirming the wide heterogeneity of mechanisms driving TNBC. CCNE1 amplification was associated with poor overall survival in patients with metastatic TNBC. CCNE1 amplification may confer resistance to chemotherapy and is associated with poor overall survival in TNBC.

31 May 2024 in Science Advances
Verified
Journal Article
Open access
EMEric H. Ma
Eric H. Ma
MDMichael S. Dahabieh
Michael S. Dahabieh
LDLisa M. DeCamp
Lisa M. DeCamp
IKIrem Kaymak
Irem Kaymak
SKSusan M. Kitchen-Goosen
Susan M. Kitchen-Goosen
RJRussell G. Jones
Russell G. Jones
Infusion of 13 C-labeled metabolites provides a gold standard for understanding the metabolic processes used by T cells during immune responses in vivo. Through infusion of 13 C-labeled metabolites (glucose, glutamine, and acetate) in Listeria monocytogenes –infected mice, we demonstrate that CD8 T effector (Teff) cells use metabolites for specific pathways during specific phases of activation. Highly proliferative early Teff cells in vivo shunt glucose primarily toward nucleotide synthesis and leverage glutamine anaplerosis in the tricarboxylic acid (TCA) cycle to support adenosine triphosphate and de novo pyrimidine synthesis. In addition, early Teff cells rely on glutamic-oxaloacetic transaminase 1 (Got1)—which regulates de novo aspartate synthesis—for effector cell expansion in vivo. CD8 Teff cells change fuel preference over the course of infection, switching from glutamine- to acetate-dependent TCA cycle metabolism late in infection. This study provides insights into the dynamics of Teff metabolism, illuminating distinct pathways of fuel consumption associated with CD8 Teff cell function in vivo.

19 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
RJRadia M. Johnson
Radia M. Johnson
XQXueping Qu
Xueping Qu
CLChu-Fang Lin
Chu-Fang Lin
LHLing-Yuh Huw
Ling-Yuh Huw
AVAvinashnarayan Venkatanarayan
Avinashnarayan Venkatanarayan
CBCarlos Bais
Carlos Bais
Most colorectal (CRC) tumors are dependent on EGFR/KRAS/BRAF/MAPK signaling activation. ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated CRC tumors. Here we show that anti-EGFR but not anti-VEGF treatment enriches for emerging ARID1A mutations in CRC patients. In addition, we find that patients with ARID1A mutations, at baseline, are associated with worse outcome when treated with cetuximab- but not bevacizumab-containing therapies; thus, this suggests that ARID1A mutations may provide both an acquired and intrinsic mechanism of resistance to anti-EGFR therapies. We find that, ARID1A and EGFR-pathway genetic alterations are mutually exclusive across lung and colorectal cancers, further supporting a functional connection between these pathways. Our results not only suggest that ARID1A could be potentially used as a predictive biomarker for cetuximab treatment decisions but also provide a rationale for exploring therapeutic MAPK inhibition in an unexpected but genetically defined segment of CRC patients.

27 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
DJDejan Juric
Dejan Juric
KSKyung Song
Kyung Song
RJRadia M. Johnson
Radia M. Johnson
MAMelissa K. Accordino
Melissa K. Accordino
PBPhilippe L. Bedard
Philippe L. Bedard
ADAnwesha Dey
Anwesha Dey
Purpose: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor–positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α. PI3K inhibitors have generally shown modest single-agent activity and have safety concerns. Patients and Methods: A first-in-human phase 1 study (NCT03006172) evaluated oral inavolisib in patients with PIK3CA-mutated solid tumors to determine the maximum tolerated dose and safety. Correlative analyses included ctDNA. Preclinical studies in cell lines and xenografts elucidated the role of FGFR2. Results: The maximum tolerated dose was 9 mg daily, with a manageable safety profile (e.g., hyperglycemia and diarrhea). Inavolisib showed linear pharmacokinetics, consistent pharmacodynamic modulation, and antitumor activity in hormone receptor–positive PIK3CA-mutated breast cancer (26% objective response rate and 45% clinical benefit rate). FGFR2 hotspot mutations in ctDNA were strongly associated with clinical benefit. Preclinically, oncogenic FGFR2 signaling enhanced inavolisib sensitivity by engaging HER3, RAS, and p85β, that facilitated mutated p110α degradation, surpassing nondegrading inhibitors. Combination therapy with FGFR2 inhibitors showed synergy and delayed resistance. Conclusions: These findings highlight a novel cooperativity between FGFR2 and p110α that boosts the effectiveness of inavolisib. The data support advancing precision oncology beyond single biomarkers to complex algorithms utilizing co-occurring alterations, suggesting that combining inavolisib with FGFR2 inhibitors may offer enhanced and more durable responses in PIK3CA/FGFR2-altered tumors.

6 January 2026
Verified
Other
Open access
DJDejan Juric
Dejan Juric
KSKyung Song
Kyung Song
RJRadia M. Johnson
Radia M. Johnson
MAMelissa K. Accordino
Melissa K. Accordino
PBPhilippe L. Bedard
Philippe L. Bedard
ADAnwesha Dey
Anwesha Dey
Foundation Medicine (FMI) FoundationACT (FACT) panel of NGS features selected by model as associated with response

6 January 2026
Verified
Other
Open access
DJDejan Juric
Dejan Juric
KSKyung Song
Kyung Song
RJRadia M. Johnson
Radia M. Johnson
MAMelissa K. Accordino
Melissa K. Accordino
PBPhilippe L. Bedard
Philippe L. Bedard
ADAnwesha Dey
Anwesha Dey
Effects of FGFR1/2/3/4 knockdown on inavolisib sensitivity